Because its use has expanded to patients with intermediate surgical risk, TAVR may be performed more frequently in patients younger than 65 years. Given uncertainty about the longterm durability of TAVR valves, we investigated how frequently TAVR is used in different age groups in the United States.
Methods | We used the National Inpatient Sample (NIS) from 2012 through 2015 (the most recent year available) and included all hospitalizations during which adult patients underwent TAVR and surgical AVR (SAVR). The NIS is a 20% stratified sample of all inpatient discharges from US nonfederal hospitals. 4 (Table) . The proportion of women receiving TAVR was 30.9% (95% CI, 24.6%-37.2%) among patients 55 years and younger and 48.7% (95% CI, 47.8%-49.7%) among those 76 years and older (P < .001).
Discussion | The number of patients overall and 65 years and younger in the NIS receiving TAVR increased annually from 2012 to 2015, as did the proportion of aortic valve replacements using TAVR. However, the distribution by age among Related article at jamainternalmedicine.com Letters TAVR procedures was unchanged. Data are lacking on the durability of the bioprosthetic valves implanted using TAVR, raising concern about use of TAVR and bioprosthetic valves in younger patients. 5, 6 Data from the NIS are only available through 2015 and current use of TAVR in 2018 has likely increased further. Younger patients may undergo TAVR due to higher risks for SAVR related to prior cardiac surgery; however, NIS does not have data on previous AVR or coronary artery bypass grafting.
Patients 65 years and younger should be informed of the limited evidence for long-term outcomes with TAVR compared with SAVR in this age group. Registries and future trials should collect longer-term follow-up data for these patients. based on assumptions about background prostate cancer mortality, intervention group compliance, control group contamination, and the rate ratios (RRs) for prostate cancer mortality among men actually receiving screening (true RR). However, using more realistic assumptions and quantities observed during the trial, those assumptions appear too optimistic, and the trial's actual power to find a mortality reduction was likely below 50%.
For the observed compliance rate of approximately 35%, the a priori assumptions would require a true RR of 0.62 to achieve the stated power. The European Randomized Study of Screening for Prostate Cancer (ERSPC) trial found an RR of 0.79; adjusted for noncompliance and thus approximating a true RR, the RR was 0.71. 2 However, the ERSPC trial had multiple screening rounds, whereas CAP had only 1. Therefore, an assumed underlying true RR of at least 0.75 to 0.80 would appear reasonable, although it could be higher (ie, closer to 1.0). The a priori assumptions also included an estimated 1720 total deaths from prostate cancer; however, only 1196 were observed, which is 30% fewer.
In addition, control group contamination (having received PSA testing) at any time during the trial was indirectly estimated as 10% to 15%. If occurring late in the trial, such testing would have little effect on mortality, so an effective contamination rate of 5% is reasonable.
The exact contamination estimate used in the original power estimate is unclear, but is presumably low. Also, based on the cluster randomized design, a coefficient of variation of 0.2 was used in the calculation; this assumption could be revised based on the observed data.
It would be of interest for the authors to perform a retrospective power analysis taking into account the above considerations. If, as appears likely, the power estimate is substantially reduced, to perhaps below 50%, then the trial results may be relatively noninformative on the question of the mortality benefit of PSA screening.
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The author has completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported. In Reply Dr Pinsky highlights the important issues of compliance, contamination, and event rates in the CAP trial and seeks clarification on how these might affect the conclusions that can be drawn. He suggests we perform a retrospective power calculation for the 10-year primary prostate cancer mortality outcome, arguing that if retrospective power is low (<50%), then the trial is uninformative regarding the effect of a single PSAbased prostate cancer screening on prostate cancer mortality.
1.
Power calculations, which are an essential part of trial design and planning, are necessarily based on assumptions. We fully described these and made them public well in advance of unblinding the data and conducting the analyses. 1 Most of our assumptions were met such as the observed compliance and contamination rates. However, as pointed out by Pinsky and noted in our discussion, the prostate cancer mortality rate was lower than anticipated when we were planning the trial. Because of this, we performed a revised power calculation prior to unblinding the data. Although our original calculation was based on identifying a true overall prostate cancer mortality RR of 0.87 (13% relative reduction) with 80% power at 5% significance, the observed number of prostate cancer deaths allowed us to identify a true RR of 0.84 (16% relative reduction). We estimated the effect of a range of PSA contamination rates; these suggested that the effect of contamination would be minimal unless it reached 20%, which it did not.
A number of authors have argued that retrospective power calculations are irrelevant and problematic (for example, Hoenig and Heisey 2 and Bacchetti 3 ) because the information provided by a trial about its target effect is completely summarized by the estimate and corresponding 95% CI.
For the CAP intervention, the estimated RR for prostate cancer mortality was 0.96 (95% CI, 0.85-1.08). Therefore, with 95% confidence, our data are consistent with up to a 15% reduction, or 8% increase, in prostate cancer mortality at a median follow-up of 10 years. Similarly, the RR for prostate cancer mortality in individuals who attended PSA screening (estimated using an instrumental variable analysis) was 0.93 (95% CI, 0.67-1.29). Thus, our data are consistent with up to a 33% reduction, or 29% increase, in prostate cancer mortality in these individuals.
It is not possible to exclude the possibility that the CAP intervention led to a modest reduction, or modest increase, in prostate cancer mortality after a median follow-up of 10 years. However, these data do not support single PSA testing for prostate cancer screening.
Because a median follow-up of 10 years may be too short to identify the effect of screening, we are planning a median
